Trial Condition(s):

Magnetic Resonance Imaging

Gadopentetate Dimeglumine as an MRI contrast agent in pediatric patients presenting with symptoms of central nervous system lesions

Bayer Identifier:

Trial_202-14_88490

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Please see attached Study Results Summary below

Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
9
Trial Dates
black-arrow
Phase
3
Could I receive a placebo?
No
Products
Magnevist (Gadopentetate Dimeglumine, BAY86-4882)
Accepts Healthy Volunteers
N/A

Where to Participate

Locations
Status
LocationsStatus

For details, please refer to trial results

Additional Information